Mybacin

Quick links to important sections

Mybacin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mybacin

What is Mybacin? The Triple-Action First-Aid Combination

Property Description
Active Ingredients Amylocaine, Bacitracin, Neomycin
Form Ointment or Cream
Pharmacological Class Combination Antibiotic and Local Anesthetic
Common Use First-aid protection and relief for minor skin injuries
Type Fixed-dose combination product

Mybacin is a recognized fixed-dose, triple-action medicinal preparation classified as a Combination Antibiotic and Local Anesthetic, designed exclusively for topical application to the skin. It is commonly available as an over-the-counter (OTC) medication intended for immediate use as a general first-aid measure. This dual-action approach, which combines two distinct infection-fighting agents with a pain reliever, provides a comprehensive initial response to minor skin trauma.

Composition and Dosage Form: The Triple-Action Formula

The Mybacin formula is characterized by its three active ingredients: Bacitracin, Neomycin, and Amylocaine. This combination leverages the Bacitracin and Neomycin antibiotics to achieve broad-spectrum coverage against a wide variety of common Gram-positive and Gram-negative bacteria that frequently colonize minor skin injuries. Neomycin is specifically recognized as an aminoglycoside antibiotic derived from Streptomyces fradiae. Amylocaine is included as a synthetic local anesthetic. Mybacin is primarily produced as a topical Ointment or Cream, forms that are recognized for their efficacy in delivering concentrated active agents directly to the necessary area, minimizing systemic exposure.

Core Benefit: How This Combination Protects and Relieves

The core benefit of Mybacin is its established capacity to deliver localized, broad-spectrum defense while providing simultaneous symptomatic pain relief. The two antibiotics work to inhibit the growth and proliferation of common bacteria, helping to support the skin’s recovery. Concurrently, the anesthetic component temporarily blocks pain signals at the nerve endings. The inclusion of the local anesthetic is intended to mitigate the mild, localized pain associated with minor skin lesions.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Mybacin?

Possible Side Effects and Safety Information: Mybacin (Bacitracin)

This section summarizes the adverse reactions and safety restrictions for Mybacin, based strictly on authoritative government regulatory documents.

Safety Profile and Restrictions

Serious Adverse Reactions (Systemic Use):

The most significant safety concern, documented by regulatory authorities, is Nephrotoxicity (severe, potentially fatal damage to the kidneys) when the drug is administered via the systemic (intramuscular) route. The regulatory label includes a Black Box Warning restricting the systemic use of Bacitracin due to this high risk. Other serious systemic risks include Anaphylaxis (a severe allergic reaction) and the potential for Neuromuscular Blockade (risk of respiratory depression or paralysis).

Adverse Reactions by System-Organ Class:

  • Renal and Urinary Disorders: Nephrotoxicity (manifesting as tubular and glomerular necrosis) with systemic use.
  • Immune System Disorders: Hypersensitivity reactions (allergic reactions).
  • Skin and Subcutaneous Tissue Disorders: Localized reactions, such as itching, rash, or burning, especially with topical use.

Safety-Related Restrictions and Considerations

The drug's safety framework is highly dependent on the method of administration:

  1. Systemic Use: The risk of nephrotoxicity is closely tied to the duration of treatment and the total cumulative dose. Systemic administration is reserved only for highly specific, life-threatening infections, typically in infants, that have failed other treatments, and is contraindicated in patients with pre-existing renal impairment.
  2. Hypersensitivity: The drug is contraindicated for use in individuals with a known sensitivity to Bacitracin.

Note: Prolonged use, even topical, carries a risk of superinfection (overgrowth of non-susceptible organisms, including fungi).

Overdose and Emergency Response

Mybacin overdose manifestations are primarily linked to systemic absorption of the active ingredients when the product is applied excessively or to large areas of compromised skin. This exposure triggers the documented risks of irreversible organ damage and acute systemic distress.

The antibiotic components carry the risk of ototoxicity and nephrotoxicity. Regulatory information documents the potential for permanent hearing loss and renal failure resulting from significant systemic neomycin exposure. Additionally, the local anesthetic component can cause acute toxicity, including manifestations such as seizures (convulsions), dizziness, hypotension, and cardiovascular collapse. These effects involve the CNS, cardiovascular, and respiratory systems, with risk of respiratory paralysis.

In the event of suspected overdose or the onset of severe symptoms, one must seek immediate medical attention. The official labeling mandates that emergency medical services must be contacted immediately for life-threatening signs such as seizures or difficulty breathing. Management is restricted to symptomatic and supportive treatment. Hospital monitoring may be required, specifically involving the monitoring of renal function and assessment of auditory function due to the identified risks. Increased risk is noted for patients with pre-existing impaired renal function.

Therapeutic Uses of Mybacin

What Mybacin Treats: Main Uses and Benefits


The medication helps address symptoms related to physical discomfort and conditions marked by increased physiological stress. This benefit is relevant in conditions associated with acute or disruptive episodes, such as cuts, scrapes, and small burns.

This antibiotic combination is utilized for easing the symptomatic burden in conditions where symptoms may intensify temporarily due to the risk of infection.

The medication is generally applied as a first-aid measure in situations where short-term symptomatic assistance is needed, assisting with maintaining functional stability and supporting the patient during difficult episodes by easing distress. The medication is applied in situations where symptoms cluster into patterns requiring supportive management, specifically relating to discomfort and susceptibility to contamination. The use of this combination may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during symptomatic periods.

Quick Fact: Relief for Localized Pain and Superficial Contamination

Regulatory References

  1. Neomycin, Polymyxin, and Bacitracin Topical: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mybacin

The official regulatory documents define eligibility for Mybacin by restricting use to specific populations and wound types.

Eligibility Scope Status Defined by Label
Populations Allowed Adults and children 2 years of age and older, for self-medication of minor, superficial skin injuries.
Contraindicated Groups Individuals with a known hypersensitivity or allergy to any ingredient, including Bacitracin, Neomycin, Amylocaine, or related aminoglycoside antibiotics.
Conditional Use Required Patients with pre-existing kidney disease or hearing problems, and women who are pregnant or breastfeeding.

Age-Related Eligibility Rules Use is restricted to ages 2 years and older. Children under 2 years must not use this product unless directed by a doctor. Geriatric use has no specific comparative data available in the regulatory records.

Eligibility-Related Restrictions The product is not authorized for deep wounds, puncture wounds, animal bites, or serious burns. It must not be used in the eyes, over large body areas, or on the irritated skin of a child’s diaper area. This product is also contraindicated for non-bacterial infections, such as those caused by fungi or viruses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Mybacin, a topical combination antibiotic, defines interactions based solely on the potential for pharmacodynamic reinforcement of systemic toxicities, which may occur only if the active components achieve substantial systemic absorption. Under standard conditions of topical use, metabolic, transporter-mediated, timing-based, and food interactions are not documented.

Pharmacodynamic Reinforcement Risks

Regulatory documents state that co-administration with other nephrotoxic medicinal products may increase the risk of renal damage if systemic absorption of Bacitracin or Neomycin occurs. Similarly, concomitant use with other ototoxic medicinal products (e.g., specific diuretics or other aminoglycosides) may pharmacodynamically reinforce the risk of inner ear damage. These interaction risks are not classified as contraindications but require regulatory caution under conditions that favor systemic exposure (e.g., prolonged application over large areas or broken skin).

Population-Specific Interaction Notes

The potential for severe nephrotoxicity and ototoxicity is officially documented as being heightened for patients with compromised renal function. This is an interaction-related consideration because reduced renal clearance may lead to toxic accumulation of absorbed active ingredients, defining a population where the use-with-caution classification carries greater significance.

Mechanism of Action

Mybacin's action is defined by two primary pharmacodynamic domains: Peripheral Sensory Nerve Signal Blockade and Dual-Target Microbial Disruption.

Peripheral Sensory Nerve Signal Blockade

This domain covers the action of Amylocaine, which exerts a reversible antagonistic effect by binding to and blocking voltage-gated sodium channels ( Na^+ channels) on peripheral sensory nerves. By preventing the necessary sodium ion influx, this mechanism interrupts the generation of the electrical action potential, resulting in the interruption of afferent sensory nerve impulse conduction.

Dual-Target Microbial Vitals Disruption

This domain combines the mechanisms of Bacitracin and Neomycin to modulate microbial viability. Bacitracin functionally inhibits the recycling of C55-PP, a lipid carrier essential for bacterial cell wall biosynthesis, resulting in defective cell wall assembly. Concurrently, Neomycin binds to the 30S ribosomal subunit, inhibiting normal protein synthesis by causing mRNA misreading, which produces faulty proteins and damages the microbial membrane. This synergistic action on both the microbial structure and protein synthesis machinery defines a multi-pathway bactericidal mechanism.

Dosage and Administration Information

How to Use Mybacin Lozenge: Administration Guidelines

This section outlines the administration of Mybacin lozenges, focusing strictly on usage instructions.

Administration Procedure

Mybacin is designated for oral administration as a lozenge. It is essential to follow the recommended technique for proper use.

Procedural Step Instruction
Route Oral (for dissolving in the mouth only)
Technique The lozenge must be allowed to dissolve slowly in the mouth. It should not be chewed or swallowed whole.
Dosing Rule Take 1 lozenge per administration.

Dosing and Frequency

The dosing schedule is determined by the maximum allowable intake per day. Use should be guided by necessity but strictly observe the maximum limit.

Dosing Parameter Guideline
Maximum Daily Dose Do not exceed 8 to 10 lozenges in a 24-hour period.
Frequency Lozenge may be taken as needed, up to the maximum daily limit.
Age Group Standard dosing is applicable for adults and children over 6 years old.

Course Duration and Restrictions

Mybacin lozenges are intended for short-term use. Consult a healthcare professional if the condition persists or worsens after a specified short duration (e.g., 2 days). This time constraint limits the continuous duration of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mybacin

Evidence for Preventing Infection in Minor Cuts and Scrapes

Research for Mybacin's antibiotic components (Bacitracin and Neomycin) has been conducted in the context of exploring the use of topical antibiotics for skin infections in minor, uncomplicated cuts and scrapes. Researchers often used Short-term Randomized Controlled Trials (RCTs) to compare the topical antibiotic combination to an inactive control, such as a petrolatum ointment. This approach was evaluated in studies focusing on episodes where symptoms become more noticeable, such as acute phases after a minor injury.

Studies reported measurements of infection rates; findings described how measured infection rates compared to the inactive control groups. Research described patterns observed in the studies related to wound evolution in the observed populations. Evidence contributes to understanding symptom patterns, particularly related to healing and recovery in the observed populations.

Research on Comfort for Minor Skin Lesions

Research on the anesthetic component, Amylocaine, focuses on the evaluation of temporary sensory changes. Studies explored its use relevant in trials assessing short-term or episodic symptom patterns, primarily associated with the initial discomfort from minor wounds, burns, or abrasions. Studies monitored outcomes related to physical discomfort. Findings described measured changes in outcomes related to physical discomfort during the study period.

What is Still Uncertain About Mybacin Research

A key limitation is that much of the available evidence comes from studies conducted on similar but not identical topical antibiotic formulations (those containing Polymyxin B instead of Amylocaine). Comparative evidence for the specific Amylocaine/Bacitracin/Neomycin combination is lacking. Overall, the evidence quality varies across studies, and while research has explored short-term changes, the long-term effects are not fully established. The results apply only to the populations studied, which primarily involved adults presenting with uncomplicated soft-tissue wounds.

Key Studies & References

  1. MedlinePlus Drug Information on Topical Antibiotic Combinations
  2. MedlinePlus Drug Information on Topical Local Anesthetics (General Use)

Frequently Asked Questions (FAQ)

Common questions about Mybacin (FAQ)

Q: Is Mybacin a type of antibiotic?

Mybacin is officially classified as a fixed-dose combination product. It contains two antibiotics, Bacitracin and Neomycin, combined with one local anesthetic, Amylocaine. This combination is intended for localized topical application.


Q: What are the major differences between Mybacin and the generic version?

According to regulatory guidance, generic versions must contain the same active ingredients, strength, and use conditions as the brand-name product. While they are considered bioequivalent, generic products may differ from Mybacin in their inactive ingredients, such as coloring agents or preservatives.


Q: Can Mybacin be used while breastfeeding is being considered?

Official documentation lists this as a Conditional Use Required category, generally based on the assessment of minimal systemic absorption versus the benefit of use. This status is defined by regulatory authorities.


Q: Are there any specific foods or drinks to avoid while using Mybacin?

Official regulatory documents for this product state that food interactions are not documented under standard topical use conditions. As the product is applied externally, the potential for metabolic interaction with ingested foods or drinks is considered low.


Q: Does Mybacin interact with caffeine?

Based on official product information, documented interactions with caffeine are not listed. As a topical product, Mybacin is designed to have minimal systemic absorption, meaning documented interactions are not expected.


Q: Are there any long-term effects of taking Mybacin?

Official research indicates the evidence focuses on short-term changes, and the long-term effects of the combination are not fully established in the regulatory record.


Q: Is the long-term use of Mybacin supported by clinical evidence?

Official documents limit the use of the product to a short-term duration. Research summaries further indicate that evidence for long-term effects is not fully established.


Q: What kind of studies have been done on Mybacin?

Studies described in official summaries typically involve Short-term Randomized Controlled Trials (RCTs) to compare the antibiotic combination to inactive controls and trials assessing the temporary sensory changes from the anesthetic component.


Q: How long after starting Mybacin will I start feeling different?

The local anesthetic component, Amylocaine, provides relief by temporarily blocking pain signals at the nerve endings. The effect is described as generally associated with rapid local onset following application.


Q: What is the typical time frame for the expected effects of Mybacin?

Mybacin is designated for short-term use only. The effects are localized and temporary; the anesthetic component is described as providing temporary relief of physical discomfort associated with the injury.


Q: Does Mybacin cause weight gain or loss?

Weight changes are not listed among the common or serious adverse reactions documented in the official safety profile for this topical combination product. Side effects are primarily localized or systemic only if significant absorption occurs.


Q: How quickly does Mybacin start to leave the body?

Official documents indicate that there is minimal absorption of the antibiotic components through normal, intact skin. This means very little of the drug enters the bloodstream for elimination.


Q: Does Mybacin interact with herbal supplements?

Regulatory documents state that interactions with other medicines or supplements are generally not documented for this product. This is due to the minimal systemic absorption that occurs under conditions of normal topical use.


Q: Can Mybacin affect how birth control pills work?

Official documents do not list an interaction with hormonal contraceptives under normal topical use conditions. Because the product is designed for minimal systemic absorption, the potential for interference is considered low.


Q: Can Mybacin cause mood changes?

Some official documents for the active ingredients have described less common effects such as mood or mental changes. These effects are primarily associated with conditions that lead to significant systemic absorption.


Q: Why do some people say Mybacin made them feel [emotional state, e.g., restless]?

The official safety profile notes that effects such as restlessness or unusual excitement have been reported as rare adverse effects. These reactions are typically related to systemic absorption of the active components.


Q: Can Mybacin affect my sleep?

The safety profiles of the active components mention effects such as somnolence (drowsiness) or restlessness. These are described as rare side effects and are related to systemic absorption.


Q: Is it normal to feel [vague side effect, e.g., slightly dizzy] when I first take Mybacin?

Dizziness is noted in regulatory documents as a possible adverse effect that may occur. This is typically observed when the components are absorbed systemically.


Q: Is Mybacin safe for people who drive or operate machinery?

Side effects like dizziness or somnolence (drowsiness) have been noted in the safety profiles of the active components. These effects are possible, particularly if systemic absorption occurs.


Q: Does Mybacin affect blood pressure or heart rate?

Regulatory documents describe the potential for the anesthetic component to affect the heart and circulatory system. If high levels are absorbed systemically, effects such as a slow heart rate (bradycardia) or low blood pressure (hypotension) could occur.


Q: Why does Mybacin have a warning about [vague safety warning, e.g., certain heart rhythms]?

Regulatory documents describe the potential for the product to cause changes in heart rate or blood pressure, such as bradycardia or hypotension. This risk is associated with a high level of the anesthetic component being absorbed systemically (e.g., through large or broken skin areas).


Q: Can Mybacin be taken with common over-the-counter pain relievers?

Official documents state that if systemic absorption of the antibiotic components occurs, combining it with other nephrotoxic medicinal products could reinforce the risk of kidney damage.


Q: What happens if Mybacin is taken for a condition it is not intended for?

Official eligibility documents specify the product is not authorized for deep wounds, burns, or non-bacterial infections. Using it, for example, on an infection caused by a fungus or virus, is not expected to be effective.


Q: If I miss a dose of Mybacin, what generally happens?

Mybacin is typically taken as needed up to a maximum daily limit for short-term use. Missing a dose would result in a period without the intended temporary relief from the anesthetic and a break in the infection-fighting action.


Q: Will I have withdrawal symptoms if I stop taking Mybacin suddenly?

Withdrawal symptoms are not listed in the product's official safety documents. Stopping the product may simply result in the return of the original symptoms (discomfort or risk of infection) it was used to relieve.

How should Mybacin be stored and disposed of?

How to Store and Dispose of Mybacin?

The storage requirements for Mybacin Ointment/Cream focus on maintaining product stability and safety, as outlined in official labeling for similar topical products.

Storage Requirement Official Condition
Temperature Store at Room Temperature (15 C to 30 C or 59 F to 86 F).
Handling Keep from freezing and store away from excess heat.
Protection Keep the container tightly closed and away from moisture and direct light.
Safety Must be kept out of the reach of children.

Expired or unused Mybacin should be disposed of according to federal guidelines. The preferred method is using a community drug take-back program. If this is unavailable, the product must be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Do not flush the product down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mybacin found in:

A-Z Index: